RedHill Unveils New Movantik Data For Opioid-Induced Constipation
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced new Movantik (naloxegol) Phase 3 study data analyses.
RedHill Biopharma Highlights Results Of Preclinical Study Of Opaganib
COVID-19 and long COVID patients are at increased risk of developing kidney damage
-
Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model
-
Renal fibrosis is a progressive process which occurs
Mid-Morning Market Update: Markets Edge Lower; Designer Brands Earnings Top Estimates
Following the market opening Tuesday, the Dow traded down 0.04% to 35,387.11 while the NASDAQ fell 0.30% to 15,219.57. The S&P also fell, dropping 0.12% to 4,523.41.
18 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Regional Health Properties Inc (NYSE: RHE) rose 50.3% to $12.49 in pre-market trading after jumping over 15% on Monday. The company, earlier during the month, reported Q2 results.
Cantor Fitzgerald Initiates Coverage On Redhill Biopharma with Overweight Rating, Announces Price Target of $22
Cantor Fitzgerald analyst Brandon Folkes initiates coverage on Redhill Biopharma (NASDAQ:RDHL) with a Overweight rating and announces Price Target of $22.
RedHill Biopharma’s Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant
RedHill Biopharma Ltd (NASDAQ:RDHL) has announced preliminary results of a new preclinical study for its COVID-19 treatment candidate, opaganib. Related: RedHill’s Novel…
The Daily Biotech Pulse: Early Approval For Ascendis’ Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 25)
